Currently, five tyrosine kinase inhibitors (TKIs—imatinib, dasatinib, nilotinib, bosutinib, and asciminib) are available for frontline therapy, but no single TKI is optimal for all patients. EUTOS ...

Explore GISTs, rare GI tumors. Discover key details on genetic causes, diagnostic methods, and cutting-edge treatment ...

Presentations at this year’s American Association for Cancer Research meeting could have a broad impact on the treatment ...

Discover why BTK inhibitors have attracted interest for treating multiple sclerosis, as a few late-stage candidates close in ...

Pausing treatment during vaccination did not improve immunity in patients with chronic lymphocytic leukemia and should not be ...

"When the first BTK inhibitor got approved by the FDA for other conditions, we all saw that follicular lymphoma should be the ...

Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...

Chronic pain, a common and debilitating condition, often leads practitioners to prescribe opioids in escalating doses.